ClinicalTrials.gg
CompletedNCT01835431Updated Jun 11, 2019Results posted

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

A Phase 3 interventional study of insulin degludec/insulin aspart and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 73 sites in 15 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2019-06-11.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
362
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin degludec · Diabetes Mellitus, Type 1.

Enrollment
4th of 39
362 · median 38
Started
2013
with 1 other
Phase 3
7 of 39
none open now
Registered
23rd of 39
by date
Lead sponsor
30 of 39
Novo Nordisk A/S

Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, this one is the 4th largest by enrollment, is one of 2 that started in 2013, is one of 7 in phase 3, and was the 23rd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in children and adolescents with type 1 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 362 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - obtained before any trial related activities. Trial related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Subjects diagnosed with type 1 diabetes mellitus - below or equal to 11.0% Exclusion Criteria: - Known hypoglycaemic unawareness or recurrent severe hypoglycaemic events as judged by the investigator - More than 1 episode of diabetic ketoacidosis requiring hospitalisation within the last 3 months prior to Visit 1 (Screening) - Any chronic disorder or significant concomitant disease, which in the investigator's opinion might jeopardise the subject's safety or compliance with the protocol

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
362 participants (actual)

Study arms

  • Experimental
    Insulin degludec/insulin aspart

    Drug: insulin degludec/insulin aspart · Drug: insulin aspart

  • Active comparator
    Insulin detemir

    Drug: insulin detemir · Drug: insulin aspart

Interventions

  • Druginsulin degludec/insulin aspart

    Drug pages: Insulin degludec · Insulin Aspart

    Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.

  • Administered s.c. with the remaining meals. Dose individually adjusted.

  • Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.

  • Administered s.c. at meal-times. Dose individually adjusted.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)

    Percentage point change in glycosylated haemoglobin A1c (HbA1c) from baseline (week 0) to 16 Weeks. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.

    Time frame: Week 0 to week 16

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose

    Change from baseline in FPG after 16 weeks of treatment. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.

    Time frame: week 0, week 16

  2. Incidence of Treatment Emergent Adverse Events (TEAEs)

    A Treatment Emergent Adverse Event (TEAE) was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day on randomised treatment.

    Time frame: After 16 weeks of treatment

  3. Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia)

    Treatment emergent hypoglycaemic episodes (PG \< 3.1 mmol/L (56 mg/dL) or severe hypoglycaemia). Confirmed hypoglycaemic episodes were defined as episodes that were either: 1. Severe (i.e. the child is having altered mental status and cannot assist in their care, is semiconscious or unconscious or in coma with or without convulsions and may require parenteral therapy (glucagon or i.v. glucose), or 2. An episode biochemically confirmed by PG value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.

    Time frame: After 16 weeks of treatment

  4. Number of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes

    The confirmed hypoglycaemic episodes occurring between 23:00 and 07:00 were considered for this endpoint

    Time frame: After 16 weeks of treatment

  5. Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill

    The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill.

    Time frame: After 16 weeks of treatment

  6. Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L)

    The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill. The ketone meaurement involved an additional finger prick and ketosis was considered present if blood ketones were higher than 1.5mmol/L

    Time frame: After 16 weeks of treatment

08

Results

Posted Nov 17, 2015

Participant flow

The trial was conducted at 63 sites in 14 countries as follows: Belgium: 3 sites; Brazil: 1 sites; Canada: 3 sites; Czech Republic 3 sites; Croatia: 2 sites; Israel: 6 sites; Macedonia: 2 sites; Poland: 3 sites; Russia: 5 sites; Serbia: 4 sites; Slovenia: 1 sites; South Africa: 2 sites; Spain: 5 sites; and United States: 23 sites.

Participant flow — Overall Study
MilestoneIDegAsp ODIDet OD/BID
Started182180
Exposed181179
Completed174168
Not completed812
Withdrew: Adverse event10
Withdrew: Other02
Withdrew: Withdrawal by subject610
Withdrew: Protocol violation10

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Haemoglobin) (%)

Percentage point change in glycosylated haemoglobin A1c (HbA1c) from baseline (week 0) to 16 Weeks. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.

Time frame:
Week 0 to week 16
Reported as:
Mean · percentage (%)
Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)
percentage (%)IDegAsp ODIDet OD/BID
Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)-0.3 ± 1.0-0.3 ± 0.9
SecondaryChange From Baseline in Fasting Plasma Glucose

Change from baseline in FPG after 16 weeks of treatment. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.

Time frame:
week 0, week 16
Reported as:
Mean · mmol/L
Change From Baseline in Fasting Plasma Glucose
mmol/LIDegAsp ODIDet OD/BID
Change From Baseline in Fasting Plasma Glucose-0.3 ± 6.4-0.1 ± 4.8
SecondaryIncidence of Treatment Emergent Adverse Events (TEAEs)

A Treatment Emergent Adverse Event (TEAE) was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day on randomised treatment.

Time frame:
After 16 weeks of treatment
Reported as:
Number · number of events
Incidence of Treatment Emergent Adverse Events (TEAEs)
number of eventsIDegAsp ODIDet OD/BID
Incidence of Treatment Emergent Adverse Events (TEAEs)501460
SecondaryNumber of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia)

Treatment emergent hypoglycaemic episodes (PG \< 3.1 mmol/L (56 mg/dL) or severe hypoglycaemia). Confirmed hypoglycaemic episodes were defined as episodes that were either: 1. Severe (i.e. the child is having altered mental status and cannot assist in their care, is semiconscious or unconscious or in coma with or without convulsions and may require parenteral therapy (glucagon or i.v. glucose), or 2. An episode biochemically confirmed by PG value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.

Time frame:
After 16 weeks of treatment
Reported as:
Number · episodes
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia)
episodesIDegAsp ODIDet OD/BID
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia)25322672
SecondaryNumber of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes

The confirmed hypoglycaemic episodes occurring between 23:00 and 07:00 were considered for this endpoint

Time frame:
After 16 weeks of treatment
Reported as:
Number · episodes
Number of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes
episodesIDegAsp ODIDet OD/BID
Number of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes316291
SecondaryNumber of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill

The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill.

Time frame:
After 16 weeks of treatment
Reported as:
Number · episodes
Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill
episodesIDegAsp ODIDet OD/BID
Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill599449
SecondaryNumber of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L)

The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill. The ketone meaurement involved an additional finger prick and ketosis was considered present if blood ketones were higher than 1.5mmol/L

Time frame:
After 16 weeks of treatment
Reported as:
Number · episodes
Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L)
episodesIDegAsp ODIDet OD/BID
Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L)612

Adverse events

Collected over Onset date on or after the first day of esxposure to randomised treatment and no later than 7 days after the last day on randomised treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegAsp OD—11/181 (6.1%)96/181 (53%)
IDet OD/BID—7/179 (3.9%)97/179 (54.2%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventIDegAsp ODIDet OD/BID
HypoglycaemiaMetabolism and nutrition disorders5/1811/179
FallInjury, poisoning and procedural complications0/1811/179
Diabetic KetoacidosisMetabolism and nutrition disorders1/1811/179
HyperglycaemiaMetabolism and nutrition disorders0/1811/179
Loss of consciousnessNervous system disorders0/1811/179
LaryngitisInfections and infestations0/1811/179
Viral infectionInfections and infestations1/1811/179
Fibula FractureInjury, poisoning and procedural complications1/1810/179
Tibia FractureInjury, poisoning and procedural complications1/1810/179
Compartment syndromeMusculoskeletal and connective tissue disorders1/1810/179
Most frequent other events
Showing 10 of 11
Most frequent other events
EventIDegAsp ODIDet OD/BID
NasopharyngitisInfections and infestations36/18132/179
HeadacheNervous system disorders23/18132/179
VomitingGastrointestinal disorders22/18112/179
Abdominal pain upperGastrointestinal disorders14/18117/179
Upper respiratory tract infectionInfections and infestations11/18117/179
PyrexiaGeneral disorders17/18110/179
Oropharyngeal painRespiratory, thoracic and mediastinal disorders9/18113/179
coughRespiratory, thoracic and mediastinal disorders13/1819/179
InfluenzaInfections and infestations9/18110/179
PharyngitisInfections and infestations3/18110/179

Baseline characteristics

The Full Analysis set (FAS) included all randomised subjects.

Age, Continuous
Age, Continuous(years)IDegAsp ODIDet OD/BIDTotal
Mean10.5 ± 4.310.8 ± 4.610.6 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)IDegAsp ODIDet OD/BIDTotal
Female9394187
Male8986175
HbA1c
HbA1c(percentage (%))IDegAsp ODIDet OD/BIDTotal
Mean8.1 ± 1.28.1 ± 1.28.1 ± 1.2
Fasting plasma Glucose (FPG)
Fasting plasma Glucose (FPG)(mmol/L)IDegAsp ODIDet OD/BIDTotal
Mean8.6 ± 4.48.1 ± 4.28.4 ± 4.3
09

Study locations

73 sites
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85053, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85724, United States
  • Novo Nordisk Investigational Site
    Sacramento, California 95816, United States
  • Novo Nordisk Investigational Site
    Aurora, Colorado 80045, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32207, United States
  • Novo Nordisk Investigational Site
    Maitland, Florida 32751, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32901, United States
  • Novo Nordisk Investigational Site
    Tallahassee, Florida 32308, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33612, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30322, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30339, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62703, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46202, United States
  • Novo Nordisk Investigational Site
    Iowa City, Iowa 52242, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21229, United States
  • Novo Nordisk Investigational Site
    Worcester, Massachusetts 01655, United States
  • Novo Nordisk Investigational Site
    Kansas City, Missouri 64111, United States
  • Novo Nordisk Investigational Site
    Buffalo, New York 14203, United States
  • Novo Nordisk Investigational Site
    Tulsa, Oklahoma 74135, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Brussels, 1090, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1200, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Curitiba, Parana 80810-040, Brazil
  • Novo Nordisk Investigational Site
    Porto Alegre, Rio Grande Do Sul 91350-250, Brazil
  • Novo Nordisk Investigational Site
    São Paulo, Sao Paulo 01228-200, Brazil
  • Novo Nordisk Investigational Site
    Vancouver, British Columbia V6H 3V4, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6A 5W9, Canada
  • Novo Nordisk Investigational Site
    Mississauga, Ontario L5B 1B8, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H3T 1C5, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec HIT 2M4, Canada
  • Novo Nordisk Investigational Site
    Zagreb, 10 000, Croatia
  • Novo Nordisk Investigational Site
    Zagreb, 10000, Croatia
  • Novo Nordisk Investigational Site
    Olomouc, 779 00, Czechia
  • Novo Nordisk Investigational Site
    Pardubice, 53203, Czechia
  • Novo Nordisk Investigational Site
    Prague 5, 15018, Czechia
  • Novo Nordisk Investigational Site
    Hyderabad, Andhra Pradesh 500034, India
  • Novo Nordisk Investigational Site
    Bangalore, Karnataka 560034, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400008, India
  • Novo Nordisk Investigational Site
    Mumbai, Maharashtra 400012, India
  • Novo Nordisk Investigational Site
    New Dehli, New Delhi 110029, India
  • Novo Nordisk Investigational Site
    Chennai, Tamil Nadu 600086, India
  • Novo Nordisk Investigational Site
    Beer Sheva, 84101, Israel
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel
  • Novo Nordisk Investigational Site
    Petah Tikva, 49202, Israel
  • Novo Nordisk Investigational Site
    Tel Aviv, Israel
  • Novo Nordisk Investigational Site
    Tel Hashomer, 52621, Israel
  • Novo Nordisk Investigational Site
    Zerifin, 70300, Israel
  • Novo Nordisk Investigational Site
    Skopje, 1000, North Macedonia
  • Novo Nordisk Investigational Site
    Gdansk, 80-952, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 04-730, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 04-736, Poland
  • Novo Nordisk Investigational Site
    Moscow, 125373, Russian Federation
  • Novo Nordisk Investigational Site
    Novosibirsk, 630048, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 191144, Russian Federation
  • Novo Nordisk Investigational Site
    Tomsk, 634050, Russian Federation
  • Novo Nordisk Investigational Site
    Ufa, 450106, Russian Federation
  • Novo Nordisk Investigational Site
    Belgrade, 11070, Serbia
  • Novo Nordisk Investigational Site
    Nis, 18 000, Serbia
  • Novo Nordisk Investigational Site
    Novi Sad, 21000, Serbia
  • Novo Nordisk Investigational Site
    Ljubljana, 1525, Slovenia
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 2193, South Africa
  • Novo Nordisk Investigational Site
    Pretoria, Gauteng 0181, South Africa
  • Novo Nordisk Investigational Site
    Mayville, KwaZulu-Natal 4058, South Africa
  • Novo Nordisk Investigational Site
    Barcelona, 08035, Spain
  • Novo Nordisk Investigational Site
    Esplugues Llobregat(Barcelona), 08950, Spain
  • Novo Nordisk Investigational Site
    Leganés, 28911, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28034, Spain
  • Novo Nordisk Investigational Site
    Madrid, 28046, Spain
10

References and documents

Publications

  • Thalange N, Deeb L, Klingensmith G, Franco DR, Bardtrum L, Tutkunkardas D, Danne T. The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials. Pediatr Diabetes. 2019 May;20(3):314-320. doi: 10.1111/pedi.12821. Epub 2019 Feb 10. PubMed 30666772 ↗
  • Battelino T, Deeb LC, Ekelund M, Kinduryte O, Klingensmith GJ, Kocova M, Kovarenko M, Shehadeh N. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial. Pediatr Diabetes. 2018 Nov;19(7):1263-1270. doi: 10.1111/pedi.12724. Epub 2018 Aug 16. PubMed 30014589 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Nov 2014, 12 months.

Results were first posted in Nov 2015, 1 year after primary completion.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 12 months is below that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2013
First posted
Apr 19, 2013
StartActual
Oct 17, 2013
Primary completionActual
Nov 7, 2014
CompletionActual
Nov 7, 2014
Results first posted
Nov 17, 2015
Last update
Jun 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01835431
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 19, 2013
Start date
Oct 17, 2013
Primary completion
Nov 7, 2014
Completion
Nov 7, 2014
Results posted
Nov 17, 2015
Last update
Jun 11, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion